SCHEMBL4074386

SCHEMBL4074386

NC(=O)c1cn(C2CC[C@@H](CO)O2)cn1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.42
LMNA P02545 4/20 0.42
ALB P02768 1/20 0.42
MAPK1 P28482 1/20 0.42
CYP1A2 P05177 1/20 0.39
ABL1 P00519 1/20 0.38
RIN1 Q13671 1/20 0.38
ADA P00813 3/20 0.36
TDP1 Q9NUW8 2/20 0.33
SMN1; SMN2 Q16637 3/20 0.32
GLA P06280 1/20 0.32
EIF4E P06730 1/20 0.32
CYP3A4 P08684 1/20 0.32
TOP1 P11387 1/20 0.32
TSHR P16473 1/20 0.32
ADORA1 P30542 1/20 0.32
THPO P40225 1/20 0.32
PMP22 Q01453 1/20 0.32
KDM4E B2RXH2 1/20 0.32
GAA P10253 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4079004 1.00 ALDH1A1 (0.42) ALDH1A1LMNAALBMAPK1CYP1A2
SCHEMBL4078996 1.00 ALDH1A1 (0.42) ALDH1A1LMNAALBMAPK1CYP1A2
SCHEMBL18963574 0.80 ABL1 (0.35) ALDH1A1LMNAALBMAPK1CYP1A2
SCHEMBL9234363 0.77 ALDH1A1 (0.42) ALDH1A1LMNAALBMAPK1CYP1A2
SCHEMBL2193016 0.76 ADRB1 (0.50) LMNAADASMN1; SMN2ADORA1HTT
SCHEMBL149648 0.76 ADRB1 (0.50) LMNAADASMN1; SMN2ADORA1HTT
SCHEMBL13186252 0.73 LMNA (0.54) ALDH1A1LMNAALBMAPK1CYP1A2
SCHEMBL13886984 0.73 LMNA (0.54) ALDH1A1LMNAALBMAPK1CYP1A2
SCHEMBL11996917 0.73 LMNA (0.54) ALDH1A1LMNAALBMAPK1CYP1A2
SCHEMBL30364250 0.73 KDM5A (0.43) ADA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7491818-B2 Nucleic acid labeling compounds AFFYMETRIX, INC. (US) 2009-02-17 US disclosed
US-7423143-B2 Nucleic acid labeling compounds AFFYMETRIX. INC. (US) 2008-09-09 US disclosed
US-7291463-B2 Incubating/condensating pseudoisocytidine molecule with (1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride to provide a pseudouridine molecule; oncology diagnosis AFFYMETRIX, INC. (US) 2007-11-06 US disclosed
US-7282327-B2 Nucleic acid labeling compounds AFFYMETRIX, INC. (US) 2007-10-16 US disclosed
US-7179905-B2 Nucleic acid labeling compounds AFFYMETRIX, INC. (US) 2007-02-20 US disclosed
US-20050287563-A1 Nucleic acid labeling compounds AFFYMETRIX, INC. 2005-12-29 US disclosed
US-6965020-B2 Nucleic acid labeling compounds AFFYMETRIX, INC. (US) 2005-11-15 US disclosed
EP-1589025-A2 Nucleic acid labeling compounds Affymetrix, Inc. (US) 2005-10-26 EP disclosed
US-20050164268-A1 Nucleic acid labeling compounds AFFYMETRIX, INC. 2005-07-28 US disclosed
EP-1124838-B1 NUCLEIC ACID LABELING COMPOUNDS AFFYMETRIX INC (US) 2005-06-01 EP disclosed
US-20040101892-A1 Nucleic acid labeling compounds AFFYMETRIX, INC. 2004-05-27 US disclosed
US-20040002595-A1 Nucleic acid labeling compounds AFFYMETRIX, INC. 2004-01-01 US disclosed
US-20030232979-A1 Nucleic acid labeling compounds AFFYMETRIX, INC. 2003-12-18 US disclosed
US-6596856-B2 For probes, comprising a heterocycle condensed with a cyclic group such as ribofuranose derivative; biotin and 5-carboxyfluorescein derivatives AFFYMETRIX, INC. 2003-07-22 US disclosed
US-20020165372-A1 Nucleic acid labeling compounds AFFYMETRIX, INC. 2002-11-07 US disclosed
WO-2000006771-A9 NUCLEIC ACID LABELING COMPOUNDS AFFYMETRIX INC (US) 2002-08-22 WO disclosed
US-20010044531-A1 Nucleic acid labeling compounds AFFYMETRIX, INC. 2001-11-22 US disclosed
US-20010018514-A1 NUCLEIC ACID LABELING COMPOUNDS AFFYMETRIX, INC. 2001-08-30 US disclosed
EP-1124838-A2 NUCLEIC ACID LABELING COMPOUNDS Affymetrix, Inc. (US) 2001-08-22 EP disclosed
WO-2000006771-A2 NUCLEIC ACID LABELING COMPOUNDS AFFYMETRIX, INC. (US) 2000-02-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002595-A1 Nucleic acid labeling compounds RNGTT, DUT, FBL ALDH1A1 760/4885LMNA 547/4885ALB 3247/4885
US-20050164268-A1 Nucleic acid labeling compounds RNGTT, DUT, FBL ALDH1A1 760/4885LMNA 547/4885ALB 3247/4885
US-20040101892-A1 Nucleic acid labeling compounds RNGTT, DUT, FBL ALDH1A1 760/4885LMNA 547/4885ALB 3247/4885
US-20010044531-A1 Nucleic acid labeling compounds RNGTT, DUT, FBL ALDH1A1 760/4885LMNA 547/4885ALB 3247/4885
US-20050287563-A1 Nucleic acid labeling compounds RNGTT, DUT, FBL ALDH1A1 760/4885LMNA 547/4885ALB 3247/4885
US-20010018514-A1 NUCLEIC ACID LABELING COMPOUNDS RNGTT, DUT, FBL ALDH1A1 760/4885LMNA 547/4885ALB 3247/4885
US-20020165372-A1 Nucleic acid labeling compounds RNGTT, DUT, FBL ALDH1A1 760/4885LMNA 547/4885ALB 3247/4885
US-20030232979-A1 Nucleic acid labeling compounds RNGTT, DUT, FBL ALDH1A1 760/4885LMNA 547/4885ALB 3247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.